open access

Vol 82, No 1 (2011)
ARTICLES
Get Citation

Treatment of obstetric cholestasis with polyunsaturated phosphatidylcholine and ursodeoxycholic acid

Beata Marciniak, Żaneta Kimber-Trojnar, Bożena Leszczyńska-Gorzelak, Jolanta Patro-Małysza, Marcin Trojnar, Jan Oleszczuk
Ginekol Pol 2011;82(1).

open access

Vol 82, No 1 (2011)
ARTICLES

Abstract

Abstract Objective: Analysis of obstetric outcomes and laboratory results depending on blood serum level of bile acids (BA) in patients with obstetric cholestasis before treatment. Material and methods: The study was conducted among 43 pregnant women with obstetric cholestasis. The study population was divided into 3 groups, depending on blood serum level of bile acids before treatment: I group (n=15) – BA 11-15μmol/l, II group (n=13) – BA 15-20μmol/l and III group (n=15) – BA > 20μmol/l. Polyunsaturated phosphatidylcholine (PPC) treatment was used in I group, ursodeoxycholic acid (UDCA) in II group and combination of them in III group. Blood serum levels of transaminases, alkaline phosphatase and bilirubin were determined before treatment and during delivery. Bile acids concentrations were also assessed during delivery in maternal serum and cord blood. Results: No significant statistical difference was observed in patients age, number of primiparas, delivery method, neonatal birth weight and Apgar score. The earliest obstetric cholestasis diagnosis was observed in III group. Earlier pregnancy termination, higher transaminases and bile acids levels before treatment, larger differences (Δ) of transaminases and bile acids levels before treatment and during delivery as well as larger Δ in bile acids levels before treatment and in cord blood during delivery were observed in III group in comparison to I group. Conclusions: It seems that combined therapy with UDCA and PPC could be considered in obstetric cholestasis, especially in case of its early onset and/or severe course.

Abstract

Abstract Objective: Analysis of obstetric outcomes and laboratory results depending on blood serum level of bile acids (BA) in patients with obstetric cholestasis before treatment. Material and methods: The study was conducted among 43 pregnant women with obstetric cholestasis. The study population was divided into 3 groups, depending on blood serum level of bile acids before treatment: I group (n=15) – BA 11-15μmol/l, II group (n=13) – BA 15-20μmol/l and III group (n=15) – BA > 20μmol/l. Polyunsaturated phosphatidylcholine (PPC) treatment was used in I group, ursodeoxycholic acid (UDCA) in II group and combination of them in III group. Blood serum levels of transaminases, alkaline phosphatase and bilirubin were determined before treatment and during delivery. Bile acids concentrations were also assessed during delivery in maternal serum and cord blood. Results: No significant statistical difference was observed in patients age, number of primiparas, delivery method, neonatal birth weight and Apgar score. The earliest obstetric cholestasis diagnosis was observed in III group. Earlier pregnancy termination, higher transaminases and bile acids levels before treatment, larger differences (Δ) of transaminases and bile acids levels before treatment and during delivery as well as larger Δ in bile acids levels before treatment and in cord blood during delivery were observed in III group in comparison to I group. Conclusions: It seems that combined therapy with UDCA and PPC could be considered in obstetric cholestasis, especially in case of its early onset and/or severe course.
Get Citation

Keywords

Cholestasis, pregnancy, bile acides and salts

About this article
Title

Treatment of obstetric cholestasis with polyunsaturated phosphatidylcholine and ursodeoxycholic acid

Journal

Ginekologia Polska

Issue

Vol 82, No 1 (2011)

Bibliographic record

Ginekol Pol 2011;82(1).

Keywords

Cholestasis
pregnancy
bile acides and salts

Authors

Beata Marciniak
Żaneta Kimber-Trojnar
Bożena Leszczyńska-Gorzelak
Jolanta Patro-Małysza
Marcin Trojnar
Jan Oleszczuk

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl